Beyond the Cut: Long-read sequencing reveals complex genomic and transcriptomic changes in AAV-CRISPR therapy for Duchenne Muscular Dystrophy
Preprint
Abstract
Adeno associated virus (AAV)-mediated delivery of CRISPR associated nucleases (AAV-CRISPR) is a promising solution to treat genetic diseases such as Duchenne Muscular Dystrophy (DMD) and is now in early clinical trials. However, genotoxicity and immunogenicity concerns have hindered clinical translation. Due to the complex etiology associated with DMD, the post-transduction consequences of double-stranded breaks induced by AAV-CRISPR in disease models are unclear. This barrier is partially conferred by conventional sequencing methods where common outcomes of AAV-CRISPR editing often escape detection. However, recent reports of novel long-read sequencing approaches permit comprehensive variant detection using a broader sequence context. Here, we comprehensively investigated genomic and transcriptomic post-AAV-CRISPR transduction consequences in myoblast cells and a DMD mouse model following intramuscular and intravenous AAV-CRISPR therapy using both long- and short-read sequencing techniques. Structural variant characterization indicates that unintended on-target large insertions and inversions are common editing outcomes. We demonstrate that combining adaptive sampling with nanopore Cas9-targeted sequencing (AS-nCATS) for long-read quantification of AAV integration is synergistic for detecting difficult-to-amplify editing events. This unbiased data suggests that full-length AAV integration is equally as probable as the on-target deletion. Further, we develop a Nanopore Rapid Amplification of cDNA Ends (nRACE-seq) pipeline for long-read detection of unknown 5’ or 3’ ends of edited transcripts. The nRACE-seq approach effectively detects the presence of AAV- Dmd chimeric transcripts, erroneous splicing events, and off-target AAV integration sites. In summary, our findings offer insights into the adaptation of AAV-CRISPR DSB-mediated therapeutics for monogenic diseases and promote the standardization of CRISPR evaluation. We highlight the importance of coupling polymerase-based and polymerase-free methods in long-read sequencing to assess editing outcomes as the field progresses toward clinical applications.Keywords
Funding Information
- NIH/NIGMS (R35GM155433)
- NIH/NIGMS (S10OD032338)
- NIH/NIBIB (R00EB023979)
This publication has 54 references indexed in Scilit:
- Pitfalls of haplotype phasing from amplicon-based long-read sequencingScientific Reports, 2016
- In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophyScience, 2016
- CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editingNucleic Acids Research, 2014
- Analyzing and minimizing PCR amplification bias in Illumina sequencing librariesGenome Biology, 2011
- 3′ End cDNA amplification using classic RACENature Protocols, 2006
- Adeno-associated virus vectors integrate at chromosome breakage sitesNature Genetics, 2004
- Investigating the Mechanism of Chromosomal Deletion: Characterization of 39 Deletion Breakpoints in Introns 47 and 48 of the Human Dystrophin GeneGenomics, 2002
- A simple and reliable 5'-RACE approachNucleic Acids Research, 2000
- Sequences of junction fragments in the deletion-prone region of the dystrophin geneGenomics, 1991
- Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individualsCell, 1987